777 results about "Antibody conjugate" patented technology

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

A multidrug linker, an antibody-drug conjugate comprising the multidrug linker, a preparation method for the antibody-drug conjugate, and uses of the multidrug linker and the antibody-drug conjugate in disease treatment. A specific structure can effectively reduce the aggregation of a multi-payload drug-antibody conjugate, thereby facilitating process scale-up. In addition, payload drugs can achieve a significant synergistic effect, thereby achieving a synergistic anti-tumor effect, effectively overcoming the resistance to drugs, and improving the therapeutic window of drugs.

The invention relates to a detection kit for epithelial-mesenchymal transition in EB virus infected thymoma and application, the detection kit comprises a quantum dot labeled antibody E-Cadherin and a quantum dot labeled antibody Vimentin, a quantum dot is coupled with a specific antibody, a thymoma paraffin section sample is dyed through the quantum dot and the specific antibody conjugate, and the EB virus infected thymoma is obtained. The conjugate can be specifically connected with an EMT related antigen expressed in the slice, so that the quantum dots can be used for qualitative or quantitative detection of the EMT-generated thymoma cells. The quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of epithelial cells and mesenchymal tissues in the thymoma microenvironment is achieved, number detection and position detection can be achieved, and EMT condition evaluation is facilitated.

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as agonistic GLP-1 peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders, such as obesity, diabetes and others.

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein, an antibody conjugate and application of the antibody conjugate, and relates to the technical field of medical biology. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1, and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity, high intermediate precision, high accuracy, consistent linear range of standard curves, fast detection and strong tolerance for the HPV16 and / or HPV18 type E2 antigen, can be used for quality control in the production process of the recombinant human HPV16 and / or HPV18 type E2 antigen, and has wide application prospects. The antigen content in the vaccine can be efficiently and accurately quantified, and the quality of the vaccine can be monitored.

The invention relates to an anti-DLL3 nano antibody, a chimeric antigen receptor and application of the anti-DLL3 nano antibody and the chimeric antigen receptor. Specifically, the invention provides a nano antibody specifically binding to DLL3 or an antigen binding fragment thereof, provides a chimeric antigen receptor related to the nano antibody or the antigen binding fragment thereof, a polynucleotide, a recombinant vector, a host cell, an antibody, an antibody conjugate, a pharmaceutical composition and a kit, and also provides related uses and methods.

Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3 / antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.

Anti-CD90 antibodies, binding fragments, and uses thereof are described. The provided antibodies and binding fragments can be used to isolate CD90 cells or to target such cells ex vivo or in vivo for a research, a diagnostic, or a therapeutic purpose. Anti-CD90 antibodies and binding fragments thereof can also be used in engineered formats to create multi-domain binding molecules, antibody conjugates, recombinant receptors, or within a recombinant protein to pseudotype viral vectors.

The invention relates to a detection kit and a detection method for EBV latent infection of epithelial cells and B cells in a thymus and salivary gland tissue microenvironment, and the detection method comprises the following steps: dyeing thymus and salivary gland tissues by coupling quantum dots and a specific antibody; the conjugate of the quantum dots and the specific antibody is combined with a specific antigen of a tissue sample to realize marking of EBV latent infection epithelial cells and B cells by the quantum dots. According to the invention, the existing multicolor immunofluorescence technology is improved, the specific antibody and the quantum dot are coupled and purified and then are directly combined with the antigen on the tissue slice to realize direct marking of the quantum dot coupled antibody on the tissue sample, so that EBV latent infection cells in the thymus and salivary gland tissue microenvironment are positioned and quantified; the virus infection condition of the patient is evaluated from the pathogenesis level, the disadvantage that the previous evaluation means are limited is overcome, and the method has good sensitivity and accuracy.

The invention provides a lipidosome STING agonist delivery system based on a PD-L1 antibody as well as a preparation method and application of the lipidosome STING agonist delivery system, and belongs to the technical field of medical biology. Preparing lipidosome by adopting an ethanol injection method and an ammonium sulfate gradient technology; the PD-L1 antibody and the STING agonist can be loaded at the same time; the liposome is prepared by adopting an ethanol injection method and an ammonium sulfate gradient technology, and the STING agonist can be wrapped in the liposome in an active drug loading manner; dSPE-PEG2000-NHS and a PD-L1 antibody are mixed and incubated according to a specific proportion by utilizing a post-insertion method to form an antibody conjugated micelle, and the antibody conjugated micelle is fused with a blank liposome to realize antibody modification; secondly, the nano-liposome has good drug carrier characteristics and can effectively protect the loaded drug, reduce the risk of enzymolysis of the drug and improve the stability of the drug in vivo, so that the liposome drug delivery system simultaneously loading the nano-liposome and the nano-liposome is successfully prepared.

The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU / OU numbering position 442 (or C442) on an antibody CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

Described herein are anti-MUC1* antibodies or antibody fragments and antibody drug complex (ADC) comprising an anti-MUC1* antibody conjugated via a linker to a toxin. The present disclosure also provides compositions comprising the antibodies and antibody drug complexes and methods for treating diseases and disorders such as cancer.

The present disclosure relates to novel antibodies binding to GPC3 or antigen-binding fragments thereof. These anti-GPC3 antibodies or fragments thereof preferably don't comprise lysine residues within their CDRs and are therefore especially suitable for conjugation. The present disclosure further relates to targeted radionuclide conjugates such as targeted actinium-225 conjugates (TACs). Preferred are TACs of formula (I) comprising the anti-GPC3 antibodies according to the present disclosure or fragments thereof. Said antibodies or antigen binding fragments thereof, and / or said antibody conjugates and / or said TACs are useful in diagnostics and / or therapy, preferably in therapy, more preferably in treating cancer, most preferably in treating hepatocellular carcinoma (HCC). Provided are pharmaceutical compositions and kits with instructions for use comprising these antibodies, functional fragments and conjugates. The disclosure further provides methods and tools to generate these antibodies, functional fragments and conjugates.

The present application relates to conjugates comprising an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell, particularly B-cell and / or lymphoma associated diseases and / or malignancies (FIG. 1).

The present invention relates to antibody conjugates which are particularly suitable for targeting CEA-expressing cells, in particular tumor cells. An antibody conjugate according to the present invention has the structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing CEA; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w'is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus hemiphyllum, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine # imgabs 0 # dimer or a pyrrolo-benzodiazepine # imgabs 1 # dimer (PBD), and analogs or prodrugs thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

Described herein are anti-MUC1* antibodies or antibody fragments and antibody drug complex (ADC) comprising an anti-MUC1* antibody conjugated via a linker to a toxin. The present disclosure also provides compositions comprising the antibodies and antibody drug complexes and methods for treating diseases and disorders such as cancer.

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

Provided herein are methods and apparatuses for analyzing mixed formulations of proteins and protein conjugates thereof. Some embodiments of the protein can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy.

The invention relates to a method for preparing an antibody-coupled drug, the antibody-coupled drug is subjected to fixed-point coupling based on an antibody Fc region N-glycosylation site, and the method comprises the following steps: (1) providing a donor containing oxazoline oligosaccharide, an antibody containing a GlcNAc motif and immobilized endoglycosidase with glucoside transfer activity; (2) covalently linking an activated donor containing the oxazoline oligosaccharide to the antibody containing the GlcNAc motif under the catalytic action of glycosidase; and one-step coupling is realized. The invention also relates to an endonuclease fusion protein which comprises the endonuclease, a Halo tag and / or a His tag which are covalently linked. The invention also relates to an immobilized glycosidase fusion protein obtained by immobilizing the glycosidase fusion protein on a support, a preloaded column filled with the immobilized fusion protein, and a purification method of the immobilized glycosidase fusion protein for an antibody conjugate.

The invention provides antibody conjugate compositions of Formula I comprising an antibody linked by conjugation to one or more target protein binder and VHL ligand (TPI-VHL) moieties. The invention also provides TPI-VHL derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the antibody conjugates through a linker or linking moiety. The invention further provides methods of treating diseases and disorders such as cancer with the antibody conjugates.

Provided herein are methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody-drug conjugate (ADC). Also provided herein are methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. Compositions, uses, and kits related thereto are also provided.

Provided are a blocking type GIPR antibody, an antigen-binding fragment thereof, an antibody conjugate thereof, and use thereof in preparing a medicament. The GIPR antibody and the antigen-binding fragment thereof have a relatively high affinity for GIPR protein and bind to the GIPR protein expressed on the cell surface, blocking the cell-activating activity of GIP. The GIPR antibody has relatively good cellular internalization activity. Pharmacokinetic research shows that the GIPR antibody and the antigen-binding fragment thereof exhibit relatively good stability in mice, with an AUC0-t up to 15,033.01 hour × μg / mL. The antibody conjugate prepared by adopting the GIPR antibody shows stable and lasting activity in reducing the weight of laboratory animal models and therefore has wide application prospects.

The present disclosure relates to improved linkers for conjugating oligonucleotidebased agents (e.g., RNAi agents) to an antibody or antibody fragment (e.g., anti-transferrin receptor (TfR1) antibodies or fragments).

Provided herein is an antibody having specificity for nucleophosprotein 1 (NPM1), which is capable of binding to nucleophosprotein 1 located on the surface of a cell; and antibody-drug conjugates (ADCs) comprising such antibodies are provided. Also provided herein are methods of treating a cancer in which NPM1 is expressed on the surface of a cancer cell by administering to a subject an NPM1-binding antibody or antibody conjugate as described herein and a chemotherapeutic drug.

The present disclosure relates to proteomics, including the detection of immune cell target proteins as examples that the disclosed methods can be used for protein detection. Methods, compositions, and systems are described for identifying the presence of proteins, including detecting immune cell proteins from a sample using a combination of multiplex immuno-PCR with antibodies conjugated to oligonucleotides comprising an antibody-specific barcode flanked by PCR priming sites; detection of barcoded amplicons obtained from immuno-PCR with encoded padlock probes comprising codes specific for the barcodes / target protein; rolling circle amplification (RCA) of the circularized padlock probes; and determination of the sequence of the codes amplified by RCA by next generation sequencing or using fluorescently labeled hybridization probes.

The present disclosure relates to antibodies and antibody conjugates that selectively bind to tissue factor and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies and antibody conjugates, such as therapeutic and diagnostic methods.

The present disclosure relates to antibodies and antibody conjugates that selectively bind to TROP2 and its isoforms and homologs, and compositions comprising the antibodies and antibody conjugates. Also provided are methods of using the antibodies and compositions, such as therapeutic and diagnostic methods.